Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: To Compare Measures of Central Nervous System Maturity of Visual Acuity, Language, Mental and Motor Skill Development in Term Infants Following Maternal Supplementation Wit the n-3 Fatty Acid Docosahexaenoic Acid (DHA) During Gestation.
Brief Summary: Polyunsaturated fatty acids known as n-3 fatty acids are essential dietary nutrients for humans, and are known to be important to reducing the risk of certain diseases, particularly those related to neural system, cardiovascular system and immune system. Among the different n-3 fatty acids, docosahexaenoic acid (DHA) is present in particularly high amounts in the brain and retina, and is accumulated in large amounts in these organs during the last trimester of fetal development and first few months after birth. The n-3 fatty acids are present in the diet as linolenic acid which is found in vegetable and seed oils, and as DHA which is only found in animal tissue fats, with fatty fish being the richest dietary source. Humans are able to convert linolenic acid to DHA, but the conversion is believed to be slow in human and possibly inadequate to support the needs for DHA for the developing brain. Information from our work and those of others has suggested that DHA is important during pregnancy, however specific evidence is lacking to show that the DHA status of pregnant women in low, or that improvement in the DHA status of Canadian women during pregnancy will have benefit to early infant an child development. There is no evidence that infants of vegans and vegetarians, or women who do not eat DHA are at risk for developmental delays. The purpose of this study is to investigate whether a dietary supplement of DHA during pregnancy has any effect on infant birth weight, or indices of infant growth, visual, mental and motor skill development.


Options:
A: Arm Label: DHA supplementation; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Docosahexanoic Acid | Arm Label: Soybean Oil; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Docosahexanoic Acid; Assigned to Arm(s): DHA supplementation | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Soybean Oil
B: Arm Label: Omega-3 polyunsaturated fatty acids; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Omega-3 polyunsaturated fatty acids | Arm Label: olive oil; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Olive oil | Intervention Type: DIETARY_SUPPLEMENT; Name: Omega-3 polyunsaturated fatty acids; Assigned to Arm(s): Omega-3 polyunsaturated fatty acids | Intervention Type: DIETARY_SUPPLEMENT; Name: Olive oil; Assigned to Arm(s): olive oil
C: Arm Label: 1; Type: OTHER; Interventions: Dietary Supplement: omega 3 fatty acids | Arm Label: 2; Type: OTHER; Interventions: Dietary Supplement: vegetable oil | Intervention Type: DIETARY_SUPPLEMENT; Name: omega 3 fatty acids; Assigned to Arm(s): 1 | Intervention Type: DIETARY_SUPPLEMENT; Name: vegetable oil; Assigned to Arm(s): 2
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: n-3 fatty acid | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: olive oil | Intervention Type: DIETARY_SUPPLEMENT; Name: n-3 fatty acid; Assigned to Arm(s): 1 | Intervention Type: DIETARY_SUPPLEMENT; Name: olive oil; Assigned to Arm(s): 2

Answer: C